Immunovant (IMVT) Competitors $14.69 -0.13 (-0.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.51 -0.18 (-1.22%) As of 08/29/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, MRNA, BBIO, VRNA, ELAN, ROIV, GRFS, RVMD, RYTM, and LEGNShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Is SLNO or IMVT more profitable? Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% Immunovant N/A -80.99%-72.23% Does the media prefer SLNO or IMVT? In the previous week, Soleno Therapeutics had 11 more articles in the media than Immunovant. MarketBeat recorded 24 mentions for Soleno Therapeutics and 13 mentions for Immunovant. Immunovant's average media sentiment score of 1.16 beat Soleno Therapeutics' score of 0.97 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, SLNO or IMVT? Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-16.35ImmunovantN/AN/A-$413.84M-$2.85-5.15 Do analysts prefer SLNO or IMVT? Soleno Therapeutics currently has a consensus price target of $115.09, suggesting a potential upside of 70.08%. Immunovant has a consensus price target of $35.20, suggesting a potential upside of 139.62%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more risk and volatility, SLNO or IMVT? Soleno Therapeutics has a beta of -2.56, meaning that its stock price is 356% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Do institutionals & insiders hold more shares of SLNO or IMVT? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummarySoleno Therapeutics beats Immunovant on 8 of the 13 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.58B$3.06B$5.66B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E Ratio-5.1520.9283.2726.61Price / SalesN/A200.54451.26176.46Price / CashN/A44.0537.7059.65Price / Book4.218.0710.556.59Net Income-$413.84M-$53.98M$3.27B$266.12M7 Day Performance-3.61%-0.88%0.47%0.17%1 Month Performance-11.61%6.20%5.93%3.03%1 Year Performance-52.46%7.13%48.79%19.98% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant2.9192 of 5 stars$14.69-0.9%$35.20+139.6%-52.6%$2.58BN/A-5.15120News CoveragePositive NewsSLNOSoleno Therapeutics4.5063 of 5 stars$66.51-3.0%$115.09+73.0%+45.3%$3.64BN/A-16.0730News CoverageAnalyst ForecastMRNAModerna4.5862 of 5 stars$25.35-6.5%$42.88+69.2%-69.0%$10.55B$3.24B0.005,800BBIOBridgeBio Pharma4.1645 of 5 stars$47.29-3.6%$61.35+29.7%+110.2%$9.38B$221.90M0.00400News CoverageAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.2909 of 5 stars$105.62+0.1%$109.00+3.2%+307.2%$9.13B$42.28M-106.6930Positive NewsELANElanco Animal Health2.7861 of 5 stars$17.80-0.6%$17.33-2.6%+20.1%$8.90B$4.48B20.709,000ROIVRoivant Sciences3.1445 of 5 stars$11.64-2.3%$16.50+41.8%-0.7%$8.14B$29.05M0.00860News CoveragePositive NewsGRFSGrifols3.5682 of 5 stars$9.82-3.3%$10.30+4.9%+9.6%$6.99B$7.81B8.3923,822Positive NewsRVMDRevolution Medicines4.3545 of 5 stars$35.67-3.6%$69.92+96.0%-9.2%$6.92BN/A-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.6139 of 5 stars$99.20-3.9%$101.57+2.4%+123.8%$6.86B$130.13M0.00140News CoveragePositive NewsLEGNLegend Biotech3.6919 of 5 stars$34.60-2.7%$73.00+111.0%-38.8%$6.53B$627.24M0.002,609Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies SLNO Competitors MRNA Competitors BBIO Competitors VRNA Competitors ELAN Competitors ROIV Competitors GRFS Competitors RVMD Competitors RYTM Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts